Special Report

GSK illo
Special Report

After a bribery scandal in China, GSK found a suspected whistleblower. The real one is still waiting in the shadows

By David Barboza — The Wire

The cliff -illustration
Special Report

Facing a broken mental health system, many U.S. teens fall off a dangerous ‘cliff’ in their care

By Megan Thielking

Atul Haven photo illustration
Special Report

Two years of halting progress and high turnover preceded Atul Gawande’s exit as Haven CEO

By Erin Brodwin and Casey Ross

Gilead White House photo illo
Special Report

With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake

By Nicholas Florko and Damian Garde

Scenario Top
Special Report

Three potential futures for Covid-19: recurring small outbreaks, a monster wave, or a persistent crisis

By Sharon Begley

Penicillium
Special Report

China has near-total control of the world’s antibiotic supply. Is America at risk as a result?

By Gardiner Harris and Alex W. Palmer — The Wire

Virus Outbreak Idaho
Special Report

Coronavirus pandemic threatens to take crushing toll on rural areas, data show

By Andrew Joseph

empty schoolyard - San Francisco
Special Report

When can we let up? Health experts craft strategies to safely relax coronavirus lockdowns

By Sharon Begley

Special Report

As the coronavirus spreads, a drug that once raised the world’s hopes is given a second shot

By Andrew Joseph

Walmart health illustration
Special Report

‘A Supercenter for health’: Walmart places a big bet on cheaper, less intimidating primary care

By Megan Thielking

Morgantown
Special Report

‘Dump it down the drain’: How contaminants from prescription-drug factories pollute waterways

By Natasha Gilbert

Medicine Hunters Part 2
Special Report

The Medicine Hunters, Part II: Toxic weed fuels a cancer-drug gold rush — and a quandary

By Eric Boodman

Medicine Hunters Part 1
Special Report

The Medicine Hunters, Part I: Before signing up for a trial, one patient wants to know if the drug will be affordable

By Eric Boodman

The future of Alzheimer's
Special Report

Forecasting Alzheimer’s: With a tsunami of new diagnoses expected, experts calculate the best ways to shift the tide

By Sharon Begley

Ting Han
Special Report

Chinese scientists came to the U.S. to pursue their dreams. Under tighter scrutiny, many are returning home

By Diana Cai

Mari-Hélène avec Tobie
Special Report

The vaccine whisperers: Counselors gently engage new parents before their doubts harden into certainty

By Eric Boodman

Pharma wins in Washington illustration
Special Report

How pharma, under attack from all sides, keeps winning in Washington

By Nicholas Florko and Lev Facher

Alzheimer's research
Special Report

The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades

By Sharon Begley

Rx overprescribing KHN
Special Report

While addiction crisis raged, many surgeons overprescribed opioids, analysis shows

By Julie Appleby and Elizabeth Lucas — Kaiser Health News

Hydrocodone Acetaminophen
Special Report

How the Kaiser-Johns Hopkins analysis was done

By Kaiser Health News

Jaci Hermstad
Special Report

When ‘right to try’ isn’t enough: Congress wants a single ALS patient to get a therapy never tested in humans

By Nicholas Florko

Special Report

Celebrity-backed shows make bold pitches to health care companies — and charge big bucks. But the experiences don’t always deliver

By Megan Thielking

TUFTS - Sackler
Special Report

‘We owe much to the Sackler family’: How gifts to a top medical school advanced the interests of Purdue Pharma

By Andrew Joseph

James High
Special Report

Their baby died during his nap. Then medical bureaucrats deepened the parents’ anguish

By Eric Boodman

Richard Sackler
Special Report

Purdue’s Sackler embraced plan to conceal OxyContin’s strength from doctors, sealed deposition shows

By David Armstrong — ProPublica

STAT Purdue illustration
Special Report

Document: Facing blame for seeding the opioid crisis, Purdue explored its next profit opportunity — treating addiction

By David Armstrong — ProPublica

Special Report

Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing

By Matthew Herper

Pharma pays up illo
Special Report

How PhRMA finally lost: the inside story of the group’s biggest lobbying failure in years

By Nicholas Florko

Genetically Modified Twins illustration
Special Report

The CRISPR shocker: How genome-editing scientist He Jiankui rose from obscurity to stun the world

By Sharon Begley and Andrew Joseph

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy